Sarepta Therapeutics (Sarepta Therapeutics) 5-Year Dividend Growth Rate

: 0.00% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

Sarepta Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Sarepta Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Sarepta Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics 5-Year Dividend Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's 5-Year Dividend Growth Rate falls into.

Sarepta Therapeutics 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Sarepta Therapeutics (NAS:SRPT) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Sarepta Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0.779
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

AB3A:Germany AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Executives

Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram	director, officer: President & CEO	2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers	director	215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf	director	OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif	officer: Chief Tech Ops Officer	215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor	director	3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac	officer: Chief Scientific Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown	officer: SVP, General Counsel	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan	officer: Chief Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica	officer: Principal Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton	officer: SVP, General Counsel	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme	officer: Senior Vice President, CFO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901